Amarox KSA

What Amarox KSA does

Amarox KSA (legal name Amarox; also operating as Saudi Amarox) is a Riyadh-headquartered pharmaceutical company founded in 2018 that manufactures and distributes high-quality generic medicines across the Middle East region, with Saudi Arabia as its primary market. The company operates a broad portfolio spanning ten therapeutic categories — cardiovascular, oncology, central nervous system, anti-infectives, anti-virals, anti-diabetics, gastrointestinal, anti-allergics, analgesic/antipyretics, and urology — with more than 40 branded generic SKUs evidenced on its product catalog (e.g., ROST, LIPOFIRATE, Veltero, XELOBINE, TRIVIRA, MELIGLPTIN, TADIL). Underlying activity is conventional oral solid and small-molecule generic manufacturing; the website also lists APIs, biosimilars, CPS, and global generics as focus areas, though the bulk of evidenced output is finished-dose generics.

The business model combines in-house manufacturing with a partner-anchored distribution architecture. Amarox supplies products exclusively through its own distribution network and through three core strategic partners — Hetero (India, APIs/generics), Camber Pharmaceuticals (US generics), and Tamer (Saudi/Middle East healthcare logistics) — making the GTM motion a channel-partner and enterprise field-sales hybrid targeting healthcare providers and patients. Pricing is not publicly disclosed and is contracted through these exclusive channels. Revenue mechanics are one-time product sales of generics, supplemented by an emerging high-value revenue-sharing model: a 2026-05-11 agreement with CEL-SCI Corporation makes Amarox the exclusive commercial distributor in Saudi Arabia for Multikine (an investigational cancer immunotherapy) under a 50/50 net revenue-share, pending SFDA approval, with an option to expand to GCC countries.

Strategic positioning is reinforced by regulatory and industry recognition: #1 ranking in the SFDA shortage and unregistered initiative for two consecutive years (2022 and 2023), highest growth rate in the Saudi pharmaceutical market in 2023, and Great Place to Work Middle East certification (Dec 2023–Dec 2024). The company participates in industry events such as the SIPHA 24 conference as a gold sponsor and the Manama Health Exhibition, and its stated mission aligns with Saudi Vision 2030 healthcare localization. Ownership is private, no parent company is disclosed, no funding rounds are recorded, and the headcount is 51–100 employees.

Name

Amarox KSA

Legal name

Amarox

Website

https://saudiamarox.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

51–100 employees

Short description

Amarox KSA is a Riyadh-based pharmaceutical company founded in 2018 that manufactures and distributes generic medicines across ten therapeutic areas to healthcare providers and patients in the Middle East, operating through exclusive distribution partnerships.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic ANDA/Regulatory Affairs & Submissions (HLAIABAJ)

akta.pro secondary industries

Specialty Pharmaceutical Distributors (HLAIAJAB), Compounding Ingredient & API Distributors (Pharma Supply) (HLAIAJAO)

Keywords

• Generic pharmaceuticals
• Pharmaceutical manufacturing
• Cardiovascular medicines
• Oncology generics
• Antidiabetic medications

Headquarters

HQ city

Riyadh

HQ country

Saudi Arabia

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

1. Generic Pharmaceutical Sales: Manufacturing and supplying high-quality generic medicines to meet diverse healthcare needs of the Middle East region through a robust distribution network.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels2 records

Core offering

Amarox KSA manufactures and supplies high-quality generic medicines and APIs across multiple therapeutic areas including cardiovascular, oncology, anti-infectives, anti-virals, central nervous system, anti-diabetics, gastrointestinal, urology, and anti-allergics. The company serves healthcare providers and patients across the Middle East region with Saudi Arabia as its primary market, operating as both manufacturer and exclusive distributor of its branded generic portfolio. Strategic global partnerships with Hetero, Camber, and Tamer support its manufacturing and supply capabilities across the region.

Product overview

Saudi Amarox is a Riyadh-based pharmaceutical company manufacturing and supplying high-quality generic medicines throughout the Middle East region. The company's product portfolio spans multiple therapeutic categories including Cardiovascular (ROST, LIPOFIRATE, BIVONEB, OLMEVASC, OLMAZIDE, Lertiv, Dabitran, Xcard, Rivax, Devasc), Nervous System (DUROTINE, ABILIRAZOLE, MULTIFIDERA, SPHINGOLIN), Oncology (Lenamid, Veltero, XELOBINE, Erloz, Tyronib), Anti-Infectives (Vanin, VIAGACIN, ZILLION), Anti-Virals (HERPTREX, VIRAD, TECABEN, VALGAN, ZOSTIVR, VIRTRA, TRIVIRA, DIVIRA), Gastrointestinals (ESOPOLE, PANTROX), Analgesic/Antipyretics (EXITOR), Anti-Allergics (EVOZYRT, FEXOFIN), Anti-Diabetics (MELIGLPTIN, meligamet, Dapxiga, Liptyn, Geuvid, Diafor), and Urology (TADIL). The company operates manufacturing facilities and has established strategic partnerships with global pharmaceutical companies including Hetero, Camber, and Tamer to expand product access throughout the region.

Differentiator

Problem solved

Functional benefit

Products and services

• Rosuvastatin (ROST) Generic statin medication for adult patients with primary hyperlipidemia and mixed dyslipidemia, pediatric patients with heterozygous familial hypercholesterolemia, and risk reduction of MI, stroke, and arterial revascularization procedures.
• Fenofibrate (LIPOFIRATE) Generic lipid-lowering agent to reduce LDL-C, Total-C, TG and Apo B, and increase HDL-C in adult patients with primary hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia, and homozygous familial hypercholesterolemia.
• Nebivolol (BIVONEB) Generic beta-blocker for management of Stage I-II hypertension, used alone or with other antihypertensives.
• Olmesartan + Amlodipine (OLMEVASC) Generic combination antihypertensive for management of mild to severe hypertension, alone or with other antihypertensives.
• Olmesartan + HCTZ (OLMAZIDE) Generic combination antihypertensive for management of patients with mild to severe hypertension, alone or with other antihypertensives.
• Lercanidipine (Lertiv) Generic calcium channel blocker for management of mild to moderate hypertension, alone or with other antihypertensives.
• Dabigatran etexilate (Dabitran) Generic direct thrombin inhibitor for treatment of venous thromboembolism events, prevention of recurrent DVT and PE, prevention of stroke and systemic embolism in non-valvular atrial fibrillation, and prophylaxis after elective hip or knee replacement surgery.
• Apixaban (Xcard) Generic Factor Xa inhibitor for treatment of DVT and PE, reducing risk of recurrence, stroke and systemic embolism in non-valvular atrial fibrillation, and prophylaxis of DVT leading to PE after hip or knee replacement surgery.
• Rivaroxaban (Rivax) Generic Factor Xa inhibitor for prevention of stroke and systemic embolism in non-valvular atrial fibrillation, treatment of DVT and PE, prevention of stroke, MI and CV death in CAD/PAD patients, and prevention of VTE after hip/knee replacements.
• Clopidogrel (Devasc) Generic antiplatelet agent for management of ACS, unstable angina, NSTEMI, STEMI, primary prevention of thromboembolism in atrial fibrillation, and secondary prevention in recent MI, stroke, CAD and PAD.
• Duloxetine (DUROTINE) Generic SNRI for treatment of depression, generalized anxiety disorder, and diabetic neuropathic pain.
• Aripiprazole (ABILIRAZOLE) Generic atypical antipsychotic for schizophrenia, acute treatment of manic and mixed episodes in Bipolar 1 disorder, adjunctive treatment of MDD, irritability associated with Autistic Disorder, and Tourette's disorder.
• Dimethyl Fumarate (MULTIFIDERA) Generic immunomodulatory agent for treatment of relapsing forms of multiple sclerosis including clinically isolated syndrome, relapsing remitting disease, and active secondary progressive disease in adults.
• Fingolimod (SPHINGOLIN) Generic sphingosine 1-phosphate receptor modulator for relapsing-remitting multiple sclerosis in adults and children (10 years and above) who have failed to respond despite treatment or have rapidly evolving severe MS.
• Lenalidomide (Lenamid) Generic immunomodulatory agent for treatment of adult patients with multiple myeloma, transfusion-dependent anemia due to MDS with 5q deletion, mantle cell lymphoma, follicular lymphoma, and marginal zone lymphoma.
• Bortezomib (Veltero) Generic proteasome inhibitor for treatment of multiple myeloma (alone or with pegylated liposomal doxorubicin, dexamethasone, melphalan, prednisone, or thalidomide) and mantle cell lymphoma in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone.
• Capecitabine (XELOBINE) Generic antimetabolite for adjuvant treatment of Duke's C colon cancer, metastatic colorectal cancer as monotherapy, metastatic breast cancer in combination with docetaxel after anthracycline failure, and as monotherapy for paclitaxel/anthracycline-resistant breast cancer.
• Erlotinib (Erloz) Generic EGFR tyrosine kinase inhibitor for treatment of metastatic NSCLC with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations, and first-line treatment of locally advanced, unresectable or metastatic pancreatic cancer in combination with gemcitabine.
• Imatinib Mesylate (Tyronib) Generic tyrosine kinase inhibitor for Ph+ CML in chronic, accelerated, or blast crisis phases, Ph+ ALL, MDS/MPD with PDGFR gene rearrangements, ASM, HES/CEL with FIP1L1-PDGFRα, unresectable/recurrent DFSP, Kit+ GIST, and adjuvant GIST treatment.
• Vancomycin (Vanin) Generic glycopeptide antibiotic for treatment of serious infections including skin/tissue infections, bone/joint infections, pneumonia, endocarditis, CNS infections, and bloodstream infections. Also for methicillin-resistant staphylococcal infections and penicillin-allergic patients.
• Moxifloxacin HCL (VIAGACIN) Generic fluoroquinolone antibiotic for treating community acquired pneumonia, skin and skin structure infections, complicated intra abdominal infections, plague, acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, and pelvic inflammatory disease.
• Linezolid (ZILLION) Generic oxazolidinone antibiotic for treatment of nosocomial pneumonia, community acquired pneumonia, complicated skin and skin structure infections including diabetic foot infections, and Vancomycin resistant Enterococcus faecium infections.
• Valaciclovir (HERPTREX) Generic antiviral for treatment of shingles, HSV infections of skin and genital herpes, cold sores, CMV prevention after organ transplants, and treatment of recurrent HSV eye infections.
• Tenofovir Disproxil (VIRAD) Generic NRTI for treatment of HIV infection in adults and adolescents (12 to less than 18 years), and treatment of chronic hepatitis B.
• Entecavir (TECABEN) Generic nucleoside analog for treatment of chronic hepatitis B virus infection in adults and children (at least 2 years) with evidence of active viral replication and persistent elevations in serum aminotransferases.
• Valganciclovir (VALGAN) Generic antiviral for treatment of CMV infections of the retina in AIDS patients and prevention of CMV infections in adults and children who received organ transplants from CMV-infected donors.
• Famciclovir (ZOSTIVR) Generic antiviral for treatment of shingles (herpes zoster), ophthalmic zoster, genital herpes infections, and prevention of recurrent genital herpes attacks.
• Lopinavir + Ritonavir (VIRTRA) Generic fixed-dose combination antiretroviral for treatment of HIV in children (2 years and older), adolescents and adults.
• Efavirenz/Emtricitabine/Tenofovir (TRIVIRA) Generic three-drug combination antiretroviral (NNRTI + NRTIs) for treatment of HIV-1 infection in adults and pediatric patients (weighing at least 40 kg), as complete regimen or in combination with other antiretrovirals.
• Tenofovir + Emtricitabine (DIVIRA) Generic fixed-dose combination NRTI for treatment of HIV-1 infection in adults and adolescents (12 to less than 18 years, weighing at least 35 kg), and for reducing risk of HIV-1 infection in high-risk populations.
• Esomeprazole (ESOPOLE) Generic proton pump inhibitor for treatment of GERD, risk reduction of NSAID-associated gastric ulcer, H. pylori eradication to reduce duodenal ulcer recurrence, and pathological hypersecretory conditions including Zollinger-Ellison syndrome.
• Pantoprazole Sodium (PANTROX) Generic proton pump inhibitor for short-term treatment (7-10 days) of GERD associated with Erosive Esophagitis and pathological hypersecretion conditions including Zollinger-Ellison syndrome.
• Etoricoxib (EXITOR) Generic COX-2 inhibitor for symptomatic relief of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute gouty arthritis, chronic musculoskeletal pain, and acute pain associated with dental surgery.
• Levocetirizine (EVOZYRT) Generic second-generation antihistamine (H1 receptor antagonist) for relief of symptoms associated with perennial allergic rhinitis and treatment of uncomplicated skin manifestations of chronic idiopathic urticaria.
• Fexofenadine (FEXOFIN) Generic second-generation antihistamine for relief of symptoms associated with seasonal allergic rhinitis in adults and children (6 years and older), and treatment of uncomplicated skin manifestations of chronic idiopathic urticaria.
• Sitagliptin (MELIGLPTIN) Generic DPP-4 inhibitor for management of T2DM, used along with diet and exercise and sometimes with other medications to reduce blood glucose levels in adults with type 2 diabetes.
• Sitagliptin + Metformin (Meligamet) Generic fixed-dose combination DPP-4 inhibitor with metformin for management of T2DM in adults.
• Dapagliflozin (Dapxiga) Generic SGLT2 inhibitor for T2DM and protection against heart failure or chronic kidney disease.
• Linagliptin (Liptyn) Generic DPP-4 inhibitor for management of T2DM, used along with diet and exercise and sometimes with other medications to reduce blood glucose levels in adults with type 2 diabetes.
• Vildagliptin (Geuvid) Generic DPP-4 inhibitor for management of T2DM, used along with diet and exercise and sometimes with other medications to reduce blood glucose levels in adults with type 2 diabetes.
• Metformin XR (Diafor) Generic extended-release biguanide for management of T2DM, used along with diet and exercise and sometimes with other medications to reduce blood glucose levels in adults.
• Tadalafil (TADIL) Generic PDE5 inhibitor for treatment of erectile dysfunction, signs and symptoms of benign prostatic hyperplasia, and both ED and BPH combined.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Four partnerships are on record, tiered core.

• CEL-SCI CorporationcoreStrategic or Co-development Partner · 11 May 2026CEL-SCI Corporation signed a strategic partnership and revenue-sharing agreement with Amarox for regulatory approval, commercialization, and distribution of its investigational cancer immunotherapy Multikine in Saudi Arabia. Under the 50/50 net revenue sharing structure, Amarox will serve as the exclusive commercial distributor pending SFDA approval, with optional expansion to GCC countries. Positions Saudi Arabia as potential first-mover market globally for Multikine.
• HeterocoreStrategic or Co-development PartnerHetero Pharma, founded in 1993, is a leading Indian pharmaceutical company specializing in generic drugs, APIs, and biosimilars, ensuring healthcare accessibility. Long-term strategic partnership with multinational global pharmaceutical company.
• CambercoreStrategic or Co-development PartnerCamber Pharmaceuticals is a US-based company providing generic medications, focusing on quality and affordability, contributing to accessible healthcare solutions.
• TamercoreStrategic or Co-development PartnerTamer is a leader in healthcare, nutrition, wellness and beauty care, responding to growing needs of Saudi and Middle East communities.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Regional players

• Gulf Pharmaceutical Industries (Julphar): UAE-based generic pharmaceutical manufacturer with strong MENA distribution footprint. Comparable generic portfolio, manufacturing-plus-distribution model, and regional ambitions overlapping Amarox's Middle East market focus.
• Tamer Group: Saudi healthcare, nutrition and wellness distributor explicitly named as an Amarox strategic partner. Comparable distribution and partnership model focused on Saudi and Middle East healthcare markets.

Broad incumbents

• Cipla: Global Indian generic pharmaceutical giant with broad therapeutic coverage and strong presence in Middle East/Africa through partnerships and distribution. Comparable to Amarox's partnership-led model and the broader Indian-to-MENA generic flow.
• Aurobindo Pharma: Indian global generic pharmaceutical and API manufacturer with broad portfolio across cardiovascular, CNS, anti-infectives, anti-virals. Comparable to Amarox in generics + API focus with cost-driven competition for MENA supply contracts.
• Dr. Reddy's Laboratories: Indian multinational generic and specialty pharmaceutical manufacturer with established MENA presence. Comparable to Amarox in generic API and finished dosage form manufacturing across cardiovascular, oncology, anti-diabetics, and anti-infectives.
• Hikma Pharmaceuticals: Jordan-headquartered multinational with broad generic and specialty pharma portfolio across MENA, US, and Europe. Established incumbent competing with Amarox in the Saudi/Middle East generics market across cardiovascular, anti-infectives and CNS.

Direct peers

• Tabuk Pharmaceuticals: Saudi-headquartered generic and specialty pharmaceutical manufacturer with regional distribution. Closely comparable to Amarox in product breadth, Saudi market focus, and generic manufacturing plus distribution model.
• Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO): Leading Saudi pharmaceutical manufacturer distributing generics and branded products across MENA. Direct competitor to Amarox in the Saudi generic pharmaceutical market across cardiovascular, CNS, anti-infectives and other therapeutic categories.
• Al Jazeera Pharmaceutical Industries (JPI): Saudi pharma manufacturer producing generics across multiple therapeutic areas with focus on local manufacturing. Direct peer in Saudi generic pharmaceutical manufacturing and supply.

Others

• Hetero Labs: Indian generic drug, API and biosimilars manufacturer explicitly identified as a long-term strategic partner of Amarox. Comparable generic manufacturing footprint and complementary Middle East distribution role.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/Amarox_ksa
• Facebookfacebook.com/profile.php
• LinkedInlinkedin.com/company/saudi-amarox

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Amarox KSA